Cochlear Ltd (Cochlear) manufactures and markets implantable hearing devices for patients suffering from hearing loss and develop integrated hearing solutions. Its major products include cochlear implant systems for patients with moderate to profound sensorineural hearing loss; bone conduction systems for patients with conductive hearing loss, mixed hearing loss or single-sided deafness; and acoustic implants for patients with moderate to severe sensorineural or mixed hearing loss. It also offers wireless accessories such as wireless mini microphone and wireless phone clip.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s research and development (R&D) focuses on developing new standard products to meet the diverse needs of its customers. The company’s primary R&D is co-located with the Australian Hearing Hub in Sydney, is focused on advanced innovation and software hub in Sweden. The company has over 550 employees working for the R&D division and has over 100 research partners in over 20 countries which include a global network of design consultants and suppliers. Cochlear had 1,700 patent and patent applications worldwide. The company invested AUD244.9 million in R&D activities in FY2023 which constitute 12% of the sales revenue of the company.